Skip to main content
SpringerLink
Log in

Radiation and Chemotherapy

  • Chapter
  • First Online:
Hilar Cholangiocarcinoma

  • 1724 Accesses

Abstract

Cholangiocarcinoma is an uncommon tumor that may occur anywhere along the intrahepatic or extrahepatic biliary tree. In the United States approximately 5,000 cholangiocarcinomas are diagnosed per year while many more biliary malignancies occur in Asia. The hepatic duct bifurcation is the most frequently involved site, and approximately 50–70 % of cholangiocarcinomas are found in this perihilar region [1]. The role of radiation therapy, chemoradiation and chemotherapy as adjuvants to surgical resection in patients with perihilar cholangiocarcinoma remains controversial. Aggressive surgical resection obtaining a negative microscopic margin offers the only chance for long-term survival. However, many patients will only be candidates for nonoperative stenting or palliative surgery aimed to provide biliary drainage and prevent cholangitis and hepatic failure. Radiation therapy, chemoradiation and/or chemotherapy also can be used in these patients with nonresectable disease in an attempt to palliate symptoms and extend survival.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Nakeeb A, Pitt HA, Coleman J, et al. Cholangiocarcinoma: a spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg. 1996;224:463–75.

    Article  PubMed  CAS  Google Scholar 

  2. Nakeeb A, Tran KQ, Black MJ, et al. Improved survival in resected biliary malignancies. Surgery. 2002;132:555–64.

    Article  PubMed  Google Scholar 

  3. Tsao JI, Nimura Y, Kamija J, et al. Management of hilar cholangiocarcinoma: comparison of an American and Japanese experience. Ann Surg. 2000;232:166–74.

    Article  PubMed  CAS  Google Scholar 

  4. Jarnagin WR, Fong Y, DeMatteo RP, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg. 2001;234:507–17.

    Article  PubMed  CAS  Google Scholar 

  5. Sakamoto Y, Kosuge T, Shimada K, et al. Prognostic factors of surgical resection in middle and distal bile duct cancer: an analysis of 55 patients concerning the significance of ductal and radial margins. Surgery. 2005;37:396–402.

    Article  Google Scholar 

  6. Woo SM, Ryu JK, Lee SH, et al. Recurrence and prognostic factors of ampullary carcinoma after radical resection: comparison with distal extrahepatic cholangiocarcinoma. Ann Surg Oncol. 2007;14:3195–201.

    Article  PubMed  Google Scholar 

  7. DeOliveira ML, Cunningham SC, Cameron JL, et al. Cholangio­carcinoma: thirty-one year experience with 564 patients at a single institution. Ann Surg. 2007;245:755–62.

    Article  PubMed  Google Scholar 

  8. Igami T, Nishio H, Ebata T, et al. Surgical treatment of hilar cholangiocarcinoma in the “new era”: the Nagoya University experience. J Hepatobiliary Pancreat Surg. 2010;17:449–54.

    Article  Google Scholar 

  9. Hirano S, Kondo S, Tanaka E, et al. Outcome of surgical treatment of hilar cholangiocarcinoma: a special reference to postoperative morbidity and mortality. J Hepatobiliary Pancreat Surg. 2010;17:455–62.

    Article  Google Scholar 

  10. Lee SG, Song GW, Hwang S, et al. Surgical treatment of hilar ­cholangiocarcinoma in the new era: the Asian experience. J Hepatobiliary Pancreat Surg. 2010;17:476–89.

    Article  Google Scholar 

  11. Unno M, Katayose Y, Rikiyama T, et al. Major hepatectomy for perihilar cholangiocarcinoma. J Hepatobiliary Pancreat Surg. 2010;17:463–9.

    Article  Google Scholar 

  12. Murakami Y, Uemura K, Sudo T, et al. Prognostic factors after ­surgical resection for intrahepatic, hilar and distal cholangiocarcinoma. Ann Surg Oncol. 2011;18:651–8.

    Article  PubMed  Google Scholar 

  13. Jarnagin WR, Ruo L, Little SA, et al. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer. 2003;98:1689–700.

    Article  PubMed  Google Scholar 

  14. Todoroki T, Ohara K, Kawamoto T, et al. Benefits of adjuvant radiotherapy after radical resection of locally advanced main hepatic duct carcinoma. Int J Radiat Oncol Biol Phys. 2000;46:581–7.

    Article  PubMed  CAS  Google Scholar 

  15. Gerhards MF, van Gulik TM, Gonzalez Gonzalez D, et al. Results of postoperative radiotherapy for resectable hilar cholangiocarcinoma. World J Surg. 2003;27:173–9.

    PubMed  Google Scholar 

  16. Sagawa N, Kondo S, Morikawa T, et al. Effectiveness of radiation therapy after surgery for hilar cholangiocarcinoma. Surg Today. 2005;35:548–52.

    Article  PubMed  Google Scholar 

  17. Pitt HA, Nakeeb A, Abrams RA, et al. Perihilar cholangiocarcinoma: postoperative radiotherapy does not improve survival. Ann Surg. 1995;221:788–97.

    Article  PubMed  CAS  Google Scholar 

  18. Serafini FM, Sachs D, Bloomston M, et al. Location, not staging, of cholangiocarcinoma determines the role for adjuvant chemoradiation therapy. Am Surg. 2001;67:839–44.

    PubMed  CAS  Google Scholar 

  19. Kim S, Kim SW, Bang YJ, et al. Role of postoperative radiotherapy in the management of extrahepatic bile duct cancer. Int J Radiat Oncol Biol Phys. 2002;54:414–9.

    Article  PubMed  Google Scholar 

  20. Nakeeb A, Pitt HA. Radiation therapy, chemotherapy and chemoradiation in hilar cholangiocarcinoma. HPB. 2005;7:278–82.

    Article  PubMed  Google Scholar 

  21. Todoroki T. Chemotherapy for bile duct carcinoma in the light of adjuvant chemotherapy to surgery. Hepatogastroenterology. 2000;47:644–9.

    PubMed  CAS  Google Scholar 

  22. Falkson G, MacIntyre JM, Moertel CG. Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer. 1984;54:965–9.

    Article  PubMed  CAS  Google Scholar 

  23. Patt YZ, Jones Jr DV, Hoque A, et al. Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract cancer. J Clin Oncol. 1996;14:2311–5.

    PubMed  CAS  Google Scholar 

  24. Takada T, Amano H, Yasuda H, et al. Study group of surgical adjuvant therapy for carcinomas of the pancreas and biliary tract; is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomised controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer. 2002;95:1685–95.

    Article  PubMed  Google Scholar 

  25. Patt YZ, Hassan MM, Aguayo A, et al. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer. 2004;101:578–86.

    Article  PubMed  CAS  Google Scholar 

  26. Gebbia V, Giuliani F, Maiello E, et al. Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study. J Clin Oncol. 2001;19:4089–91.

    PubMed  CAS  Google Scholar 

  27. André T, Tournigand C, Rosmorduc O, GERCOR Group, et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol. 2004;15:1339–43.

    Article  PubMed  Google Scholar 

  28. Kornek GV, Schuell B, Laengle F, et al. Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. Ann Oncol. 2004;15:478–83.

    Article  PubMed  CAS  Google Scholar 

  29. Dingle BH, Rumble RB, Brouwers MC. The role of gemcitabine in the treatment of cholangiocarcinoma and gallbladder cancer: a systematic review. Can J Gastroenterol. 2005;19:711–6.

    PubMed  Google Scholar 

  30. Murakami Y, Uemura K, Sudo T, et al. Gemcitabine-based adjuvant chemotherapy improves survival after aggressive surgery for hilar cholangiocarcinoma. J Gastrointest Surg. 2009;13:1470–9.

    Article  PubMed  Google Scholar 

  31. Rao S, Cunningham D, Hawkins RE, et al. Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. Br J Cancer. 2005;92:1650–4.

    Article  PubMed  CAS  Google Scholar 

  32. Ducreux M, Van Cutsem E, Van Laethem JL, et al. A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial. Eur J Cancer. 2005;41:398–403.

    Article  PubMed  CAS  Google Scholar 

  33. Ueno H, Okusaka T, Ikeda M, et al. Phase II study of S-1 in patients with advanced biliary tract cancer. Br J Cancer. 2004;91:1769–74.

    Article  PubMed  CAS  Google Scholar 

  34. Sasaki T, Isayama H, Nakai Y, et al. Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol. 2010;65:1101–7.

    Article  PubMed  CAS  Google Scholar 

  35. Valle JW, Wasan H, Johnson P, et al. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study—the UK ABC-01 study. Br J Cancer. 2009;101:621–7.

    Article  PubMed  CAS  Google Scholar 

  36. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine ­versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–81.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Temple University Health System, Philadelphia, PA, 19190, USA

    H. A. Pitt MD

  2. Department of Surgery, Indiana University, Indianapolis, IN, USA

    A. Nakeeb MD

Authors
  1. H. A. Pitt MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Nakeeb MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H. A. Pitt MD .

Editor information

Editors and Affiliations

  1. , Faculty of Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong, N/A, Hong Kong SAR

    W.Y. Lau

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media Dordrecht and People's Medical Publishing House

About this chapter

Cite this chapter

Pitt, H.A., Nakeeb, A. (2013). Radiation and Chemotherapy. In: Lau, W. (eds) Hilar Cholangiocarcinoma. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-6473-6_31

Download citation

  • DOI: https://doi.org/10.1007/978-94-007-6473-6_31

  • Published:

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-007-6472-9

  • Online ISBN: 978-94-007-6473-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation